ADC Therapeutics has filed a patent for antibody conjugates that target prostate-specific membrane antigen (PSMA) and are linked to cytotoxic warheads. The patent claims a specific antibody drug conjugate formula and includes the amino acid sequences of the antibody’s variable regions. The invention has potential applications in the treatment of prostate cancer. GlobalData’s report on ADC Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on ADC Therapeutics, nanoparticle drug conjugates was a key innovation area identified from patents. ADC Therapeutics's grant share as of June 2023 was 1%. Grant share is based on the ratio of number of grants to total number of patents.
Antibody drug conjugate for prostate-specific membrane antigen (psma)
A recently filed patent (Publication Number: US20230201366A1) describes an antibody drug conjugate for the treatment of prostate cancer. The conjugate consists of an antibody that binds to prostate-specific membrane antigen (PSMA) and is conjugated to a DNA-binding cytotoxin called pyrrolobenzodiazepine (PBD) dimer. The antibody has specific amino acid sequences in its heavy and light chain variable regions. The drug linker used in the conjugate is also specified.
The patent claims various aspects of the conjugate. Claim 1 describes the overall structure of the antibody drug conjugate, specifying the antibody, cytotoxin, and drug linker. Claims 2 and 3 provide alternative amino acid sequences for the antibody's heavy and light chain variable regions. Claim 4 states that the conjugate can have a specific value for a variable called "m." Claim 5 describes a specific double bond formation between two atoms in the conjugate. Claim 6 mentions the presence of a specific linker between the cytotoxin and the antibody. Claim 7 introduces the concept of a cleavable linker between the cytotoxin and the antibody. Claim 8 provides additional details about the linker used in the conjugate. Claim 10 mentions the conjugation of the cytotoxin to the antibody at specific glycosylation sites. Claim 12 describes a method of treating prostate cancer using the antibody drug conjugate.
The patent also includes claims related to the drug linker (L-D) used in the conjugate. Claims 13 and 14 describe the structure and attachment of the drug linker to the antibody at a specific glycosylation site. Claims 15 and 16 provide further details about the glycosylation site and the residues involved. Claims 17 and 18 repeat the information from claims 13 and 14. Claim 19 specifies the glycosylation site in more detail. Finally, claims 20 and 21 introduce the concept of a cleavable linker sequence, specifically mentioning cathepsin cleavable sequences.
Overall, this patent describes a specific antibody drug conjugate for the treatment of prostate cancer. The conjugate consists of an antibody that binds to PSMA and is conjugated to a DNA-binding cytotoxin. The patent provides detailed information about the structure of the conjugate, including the amino acid sequences of the antibody's variable regions and the specific drug linker used. The patent also claims methods of treating prostate cancer using the conjugate and provides additional details about the attachment of the drug linker to the antibody at specific glycosylation sites.
To know more about GlobalData’s detailed insights on ADC Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
